The global nuclear medicine market size is anticipated to around USD 16.2 billion by 2026, this market is anticipated to grow with 9.5% CAGR during the forecast time period. Increase in healthcare spending across the globe drives the demand for nuclear medicine market. Also need for advance diagnostic treatment for cancers are the other factor driving the global nuclear medicine market.
The burden of ceaseless infections or chronic diseases, for example, cancer and heart issue is on an ascent. Nuclear medicine is generally utilized for analysis or diagnosis and in addition treatment of such disorders.
Expanding occurrence of these disorders directly affects utilization of radio pharmaceuticals. According to information distributed by the World Health Organization (WHO), malignant growth is the second driving reason for death around the world and in 2015, represented 8.8 million death. This is foreseen to drive need for radiop harmaceuticals in the years to come.
Requirement for ahead of schedule and precise analytic strategies, combined with developing need for better treatments, is driving the market. Expanding occurrence of disease and cardiovascular issue is likewise contributing toward market development as nuclear medicine has demonstrated fairly precise in the determination and treatment of such conditions.
As per the World Health Organization (WHO) in February 2015, the quantity of new instances of Cancer is required to develop by around 70% throughout the following two decades. All around, 8.8 million individuals died from cancer growth in 2015. Cancer represents one out of each six deaths all around.
Market By Product
Market By Application
Market By Geography
North America initiated the market in 2018, representing an offer of over 44.0% that year. This can be ascribed to progressive healthcare infrastructure in the district, particularly in U.S. Increasing burden of disease and different cardiovascular disarranges is likewise a high effect rendering factor driving the market.
Asia Pacific is foreseen to enroll the most astounding CAGR of 10.9% during the forecast period. Demand for nuclear medicine is expanding in developing markets, for example, China and India because of rising disposable income, enhancing medicinal healthcare standards, and favourable reforms in foreign policies. China is overwhelms the Asia Pacific market and is probably going to clutch its lead position through 2026.
Market companies are concentrating on implementing new strategies for instance regional expansion, partnerships, mergers and acquisitions, new product launches, and distribution agreements to surge their revenue share. The major players associated with the nuclear medicine are Eczacibasi-Monrol, Eckert & Ziegler Group, NTP Radioisotopes SOC Ltd., Mallinckrodt Pharmaceuticals, Australian Nuclear Science & Technology Organization (ANSTO), GE Healthcare, Nordion, Inc., Jubilant Life Sciences, The Institute of Radioelements, and Bracco Imaging S.p.A.